Aug. 22, 2011 -- An experimental drug that has been shown to be effective in treating ovarian cancer in patients with BRCA1 or BRCA2 gene mutations also appears to work in some patients without the mutations.
The drug olaparib is one of several experimental treatments that block the activity of the protein PARP, which, like BRCA, is involved in DNA repair.
In earlier trials, PARP inhibitors have been shown to promote tumor cell death in breast and ovarian cancer patients with BRCA mutations by preventing the cells from repairing their DNA.
But the new study is the first to suggest the drugs may prove effective in a broader group of patients with non-inherited cancers who have few treatment options, lead researcher Karen Gelmon, MD, of Vancouver, Canada’s BC Cancer Agency tells WebMD.
Prior to entering the study, the patients had been treated with an average of three different chemotherapy regimens, and some had received as many as 10 different treatments.
Some of the patients carried the BRCA1 or BRCA2 mutations while others did not.
All of the patients were treated with 400 milligrams of olaparib twice a day for a month between July 2008 and September 2009. Side effects were described as well tolerated and included fatigue, nausea, vomiting, and decreased appetite.
Ovarian cancer patients who took part in the trial had high-grade serous tumors, which share similar traits to tumors in women with BRCA mutations.
After taking the experimental drug for four weeks, 41% of the ovarian cancer patients with BRCA mutations and 24% of those without a mutation showed substantial shrinkage in the size of their tumors.
No Activity in Triple-Negative Breast Cancers
Responses were not seen in breast cancer patients with triple-negative tumors -- tumors that do not respond to hormonal treatments or those targeting HER2 receptors.
While the response in these breast cancer patients was disappointing, the response in the ovarian cancer patients suggests that the drug may have a role in the treatment of patients without BRCA mutations, oncologist Melinda Telli, MD, tells WebMD.